Trial Details
RecruitingBasic Information
| Clinical ID | c2343 |
|---|---|
| Identifier | ACTRN12621001498886 |
| Trial Title | Comparison between switching from intravenous to subcutaneous infliximab on the maintenance of clinical and biochemical remission in patients with inflammatory bowel disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Ulcerative colitis;Crohn's disease; Ulcerative colitis Crohn's disease;Inflammatory and Immune System - Autoimmune diseases;Oral and Gastrointestinal - Inflammatory bowel disease |
| Interventions | Intervention - switching patients from intravenous infliximab to subcutaneous infliximab for the treatment of inflammatory bowel disease - subcutaneous infliximab: administered via a pre-filled syringe at a dose of 120mg subcutaneously every 2 weeks - total duration: 48 weeks - adherence monitored by: initial supervision by subcutaneous infliximab nurse, and infliximab levels completed at week 24 and 48. |
Participant Information
| Sponsor | Concord Repatriation General Hospital |
|---|---|
| City | - |
| Country/Region | Australia |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, ELDER, OLDER_ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE4 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |